The abstract is read at the publisher; the summary is JClub's.
ESCAPE provides an off-target-free chemogenetic pair for the adenosine A2A receptor, enabling receptor-specific control of signaling with a clinically validated antagonist and an engineered, antagonist-insensitive mutant.
- Why it matters: Pharmacology can reveal GPCR roles but may suffer from off-target effects, limiting physiological interpretation. ESCAPE addresses this by enabling receptor-specific dissection.
- What they did: The platform pairs a clinically validated A2A R antagonist with an engineered A2A R mutant that is insensitive to the antagonist yet remains responsive to adenosine, then tests effects in neuron-like cells.
- The result: Using this pair, A2A R activity is linked to neurite outgrowth under hypoxic conditions in neuron-like cells, and the approach is shown to generalize to other class A GPCRs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.